| Dr Marine Demirjian, MD | |
|
1131 N Pacific Ave, Glendale, CA 91202 | |
| (818) 558-5828 | |
| (888) 717-1542 |
| Full Name | Dr Marine Demirjian |
|---|---|
| Gender | Female |
| Speciality | Allergy/immunology |
| Experience | 16 Years |
| Location | 1131 N Pacific Ave, Glendale, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669624219 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207KA0200X | Allergy & Immunology - Allergy | A111311 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allergy And Asthma Treatment Center P C | 8022249762 | 2 |
News Archive
A research team from Emory University School of Medicine investigated the role between adiponectin and leptin in obesity-related carcinogenesis. Their findings, published in the November issue of Hepatology, suggest that the protein hormone adiponectin has potential for inhibiting the oncogenic actions of leptin, namely in hepatocellular carcinoma (HCC), and could offer a promising therapy for the disease.
Researchers are close to commercializing a new type of medical imaging technology that could diagnose cardiovascular disease by measuring ultrasound signals from molecules exposed to a fast-pulsing laser.
FUJIFILM Holdings America Corporation, today announced that FUJINON INC. will be restructured into two subsidiaries - one will report into FUJIFILM North America Corporation and the other into FUJIFILM Medical Systems U.S.A., Inc. This restructuring of Fujinon into two subsidiary companies will support Fujifilm's objective of strengthening its sales organizations to realize future growth.
The Multiple Myeloma Research Foundation (MMRF) today announced that two San Diego area biotech firms, Intellikine and Tragara Pharmaceuticals, Inc. will receive funding via its MMRF Biotech Investment Award program. The MMRF Biotech Investment Awards represent a multi-year research grant commitment to fund the early-stage drug development of novel compounds and approaches that show potential in treating multiple myeloma. Based on the companies' achievement of clearly defined milestones, the MMRF will commit a total of $1,000,000 to each company by the end of 2011.
› Verified 5 days ago
| Entity Name | Allergy And Asthma Treatment Center P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225467590 PECOS PAC ID: 8022249762 Enrollment ID: O20140324000527 |
News Archive
A research team from Emory University School of Medicine investigated the role between adiponectin and leptin in obesity-related carcinogenesis. Their findings, published in the November issue of Hepatology, suggest that the protein hormone adiponectin has potential for inhibiting the oncogenic actions of leptin, namely in hepatocellular carcinoma (HCC), and could offer a promising therapy for the disease.
Researchers are close to commercializing a new type of medical imaging technology that could diagnose cardiovascular disease by measuring ultrasound signals from molecules exposed to a fast-pulsing laser.
FUJIFILM Holdings America Corporation, today announced that FUJINON INC. will be restructured into two subsidiaries - one will report into FUJIFILM North America Corporation and the other into FUJIFILM Medical Systems U.S.A., Inc. This restructuring of Fujinon into two subsidiary companies will support Fujifilm's objective of strengthening its sales organizations to realize future growth.
The Multiple Myeloma Research Foundation (MMRF) today announced that two San Diego area biotech firms, Intellikine and Tragara Pharmaceuticals, Inc. will receive funding via its MMRF Biotech Investment Award program. The MMRF Biotech Investment Awards represent a multi-year research grant commitment to fund the early-stage drug development of novel compounds and approaches that show potential in treating multiple myeloma. Based on the companies' achievement of clearly defined milestones, the MMRF will commit a total of $1,000,000 to each company by the end of 2011.
› Verified 5 days ago
| Entity Name | Allergy And Asthma Specialist Doctors, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245794866 PECOS PAC ID: 3779817432 Enrollment ID: O20190628002637 |
News Archive
A research team from Emory University School of Medicine investigated the role between adiponectin and leptin in obesity-related carcinogenesis. Their findings, published in the November issue of Hepatology, suggest that the protein hormone adiponectin has potential for inhibiting the oncogenic actions of leptin, namely in hepatocellular carcinoma (HCC), and could offer a promising therapy for the disease.
Researchers are close to commercializing a new type of medical imaging technology that could diagnose cardiovascular disease by measuring ultrasound signals from molecules exposed to a fast-pulsing laser.
FUJIFILM Holdings America Corporation, today announced that FUJINON INC. will be restructured into two subsidiaries - one will report into FUJIFILM North America Corporation and the other into FUJIFILM Medical Systems U.S.A., Inc. This restructuring of Fujinon into two subsidiary companies will support Fujifilm's objective of strengthening its sales organizations to realize future growth.
The Multiple Myeloma Research Foundation (MMRF) today announced that two San Diego area biotech firms, Intellikine and Tragara Pharmaceuticals, Inc. will receive funding via its MMRF Biotech Investment Award program. The MMRF Biotech Investment Awards represent a multi-year research grant commitment to fund the early-stage drug development of novel compounds and approaches that show potential in treating multiple myeloma. Based on the companies' achievement of clearly defined milestones, the MMRF will commit a total of $1,000,000 to each company by the end of 2011.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Marine Demirjian, MD 1131 N Pacific Ave, Glendale, CA 91202-2358 Ph: (818) 558-5828 | Dr Marine Demirjian, MD 1131 N Pacific Ave, Glendale, CA 91202 Ph: (818) 558-5828 |
News Archive
A research team from Emory University School of Medicine investigated the role between adiponectin and leptin in obesity-related carcinogenesis. Their findings, published in the November issue of Hepatology, suggest that the protein hormone adiponectin has potential for inhibiting the oncogenic actions of leptin, namely in hepatocellular carcinoma (HCC), and could offer a promising therapy for the disease.
Researchers are close to commercializing a new type of medical imaging technology that could diagnose cardiovascular disease by measuring ultrasound signals from molecules exposed to a fast-pulsing laser.
FUJIFILM Holdings America Corporation, today announced that FUJINON INC. will be restructured into two subsidiaries - one will report into FUJIFILM North America Corporation and the other into FUJIFILM Medical Systems U.S.A., Inc. This restructuring of Fujinon into two subsidiary companies will support Fujifilm's objective of strengthening its sales organizations to realize future growth.
The Multiple Myeloma Research Foundation (MMRF) today announced that two San Diego area biotech firms, Intellikine and Tragara Pharmaceuticals, Inc. will receive funding via its MMRF Biotech Investment Award program. The MMRF Biotech Investment Awards represent a multi-year research grant commitment to fund the early-stage drug development of novel compounds and approaches that show potential in treating multiple myeloma. Based on the companies' achievement of clearly defined milestones, the MMRF will commit a total of $1,000,000 to each company by the end of 2011.
› Verified 5 days ago
Peter J Parker, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 1100 W Glenoaks Blvd, Glendale, CA 91202 Phone: 818-546-2626 Fax: 818-546-1056 |